Schering’s Vicriviroc R&D To Focus On Treatment-Experienced HIV Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
The decision to focus registration on treatment-experienced patients follows the recent termination of a Phase II trial in treatment-naïve HIV patients.
You may also be interested in...
Pfizer’s Maraviroc Unanimously Recommended For Accelerated Approval
However, members of FDA’s Antiviral Drugs Advisory Committee voice numerous concerns, recommending additional data or analysis for full approval of the CCR5 antagonist.
Pfizer’s Maraviroc Unanimously Recommended For Accelerated Approval
However, members of FDA’s Antiviral Drugs Advisory Committee voice numerous concerns, recommending additional data or analysis for full approval of the CCR5 antagonist.
FDA Seeking Input On Long-Term Follow-Up For HIV Entry Inhibitors
FDA and the Forum for Collaborative HIV Research will hold a public meeting on Jan. 18 to discuss the appropriate collection of long-term follow-up data for CCR5 antagonist clinical trials.